Citizens Financial Group Inc RI lifted its stake in Humana Inc (NYSE:HUM) by 2.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,188 shares of the insurance provider’s stock after purchasing an additional 33 shares during the period. Citizens Financial Group Inc RI’s holdings in Humana were worth $374,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in HUM. Wealthfront Advisers LLC raised its stake in Humana by 17.8% in the fourth quarter. Wealthfront Advisers LLC now owns 4,107 shares of the insurance provider’s stock valued at $1,505,000 after buying an additional 621 shares in the last quarter. Balasa Dinverno & Foltz LLC acquired a new stake in Humana in the fourth quarter valued at $446,000. Clarius Group LLC raised its stake in Humana by 4.8% in the fourth quarter. Clarius Group LLC now owns 1,190 shares of the insurance provider’s stock valued at $433,000 after buying an additional 55 shares in the last quarter. Tompkins Financial Corp acquired a new stake in Humana in the fourth quarter valued at $55,000. Finally, Convergence Investment Partners LLC acquired a new stake in Humana in the fourth quarter valued at $206,000. Hedge funds and other institutional investors own 93.22% of the company’s stock.
Shares of NYSE:HUM opened at $395.27 on Friday. The business’s 50 day simple moving average is $360.31 and its 200-day simple moving average is $345.30. The firm has a market capitalization of $51.72 billion, a price-to-earnings ratio of 20.29, a price-to-earnings-growth ratio of 1.71 and a beta of 0.91. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.66 and a quick ratio of 1.66. Humana Inc has a 12 month low of $208.25 and a 12 month high of $412.70.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $5.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.84 by $0.56. The business had revenue of $18.94 billion for the quarter, compared to analyst estimates of $18.49 billion. Humana had a return on equity of 21.02% and a net margin of 3.86%. The company’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.48 EPS. On average, equities analysts anticipate that Humana Inc will post 18.55 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.625 per share. The ex-dividend date of this dividend is Monday, June 29th. This represents a $2.50 annualized dividend and a dividend yield of 0.63%. Humana’s dividend payout ratio is currently 13.99%.
A number of analysts have weighed in on the company. SunTrust Banks raised their price target on Humana from $400.00 to $440.00 and gave the company a “hold” rating in a research note on Thursday. UBS Group lifted their target price on Humana from $321.00 to $406.00 and gave the stock a “neutral” rating in a research report on Thursday, January 23rd. Cantor Fitzgerald lifted their target price on Humana from $345.00 to $400.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Oppenheimer lifted their target price on Humana from $400.00 to $425.00 and gave the stock an “outperform” rating in a research report on Thursday, April 30th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $425.00 target price on shares of Humana in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Humana currently has an average rating of “Buy” and an average target price of $405.42.
In related news, Director David A. Jr/Ky Jones sold 5,800 shares of Humana stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $256.19, for a total transaction of $1,485,902.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.42% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Story: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.